Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Viatris (VTRS) PT Lowered to $19 at BMO Capital
March 1, 2022 7:16 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Viatris (NASDAQ: VTRS) to $19.00 (from $23.00) while maintaining an Outperform rating.
The analyst commented, "4Q was in-line, but 2022 guidance was light (though FX is factor, guidance seems conservative). Bigger focus taking stock down was Biocon... More
Viatris (VTRS) PT Lowered to $10 at Cowen
February 28, 2022 12:16 PM ESTCowen analyst Ken Cacciatore lowered the price target on Viatris (NASDAQ: VTRS) to $10.00 (from $15.00) while maintaining a Market Perform rating following weak Q4 results and guidance, and plans to divest some franchises.
The analyst commented, "Following another weak result and 2022 guidance that... More
